3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
28
Carcinoma, Non-Small-Cell Lung
11
Liver Neoplasms
7
Lung Neoplasms
5
Urinary Bladder Neoplasms
4
Small Cell Lung Carcinoma
4
Diabetes Mellitus, Insulin-Dependent, 12
4
Pancreatic Neoplasms
3
Neoplasms
3
Colorectal Neoplasms
3
Cholangiocarcinoma
3
Biliary Tract Neoplasms
3
Adenocarcinoma Of Esophagus
3
Neoplasm Metastasis
2
Mesothelioma, Malignant
2
Mesothelioma
2
Fallopian Tube Neoplasms
2
Carcinoma
2
Urothelial Cancer
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Unresectable Hepatocellular Carcinoma
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Malignancies
1
Seminoma
1
Rare Diseases
1
Interventions
pembrolizumab
45
Paclitaxel
42
Carboplatin
34
Bevacizumab
18
Specimen Handling
17
Letrozole
16
lenvatinib
13
Magnetic Resonance Spectroscopy
12
dostarlimab
11
Cisplatin
11
Biopsy
11
Taxes
10
olaparib
9
Fulvestrant
9
Doxorubicin
9
abemaciclib
8
Megestrol Acetate
8
Docetaxel
8
durvalumab
7
atezolizumab
7
Nivolumab
7
Gemcitabine
7
Blood Specimen Collection
7
palbociclib
6
Oxaliplatin
6
Observation
6
Fluorouracil
6
niraparib
5
Surveys and Questionnaires
5
Progestins
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
tremelimumab
×
1 year
×
Clear all
NCT06680739
2026-06-01
SERPENTINE
Vall d'Hebron Institute of Oncology
Phase 2
Recruiting
60 enrolled